In this OncLiveTV video, “Graham Dixon, PhD, chief scientific officer, Onxeo, director, R&D, Onxeo, discusses a phase I study investigating the combination of belinostat (Beleodaq) plus CHOP in patients with peripheral T-cell lymphoma.”

Learn more about lymphoma here: http://bit.ly/1UwWKe6

Print This Page